Glaukos (GKOS) logo

Glaukos (GKOS) stock

Eye treatments , market cap $15B

After-hours
$233.08
0.00%

Close $233.08 -4.18%

Why is GKOS down?

Down 4.2% today, while its medical device peers are up 0.8%; no story names it yet.

Ahead of the market

Up 390% over five years while the S&P 500 rose 67%.

  • Revenue grew 17.7% a year against its 3 peers' median of 7.7%; Glaucoma revenue went from $237.0M to $421.1M.

Sources: Price history, Nov 17, 2026; Annual reports, Dec 31, 2025; Peers' annual reports, Nov 17, 2026; 10-K segment note, Feb 23, 2026

Tell me next time GKOS moves

Free account, no card. An optional alert when GKOS moves or its score changes.Pro, 7 days free with a card. An optional alert when GKOS moves or its score changes.

Or see it live, free until Friday morning. No account.
1 more reason, free with an account →3 more reasons why GKOS beats the market, from its filings, with the timeline and its peers, for Pro members.
Quality Score
12
Above Average
In its industry
#15of 87
Checks firing
4of 14
Trending up
From 52-week high
-8.7%
under its best in a year

GKOS's Quality Score fell 2 points on Wed, Nov 18, to 12.

See GKOS's 14 chart checksSee it live, free until Friday morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Key facts on GKOS

Key facts on GKOS
The chartStronger than 97% of stocks above every average
Latest filing8-K, Oct 28 Reported its quarterly results
1 more reason behind GKOS's 12, free with an account →5 more reasons behind GKOS's 12, for Pro members.

GKOS in the news

TodayNo story names it yet.

What's next

Wed Nov 18: Jefferies 17th Annual London Global…Investor conference · date confirmed.

2 more dates ahead: conferences, for Pro members.

GKOS catalysts

Coming up

After its last 4 reports it closed +18.6% on average, higher 4 of 4 times.

32 past catalysts since 2018, with sizes and sources, for Pro members.

Why GKOS scores 12

Above Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means

  • +4Chart checks 4 of 14 firing right now, one point each
  • +4Long-term trend above a rising 200-⁠day average, near its 52-⁠week high, at a multi-⁠year high
  • Run-up adds
  • Size adds
  • Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
  • Persistence adds
  • Insider trades subtracts

No effect today: Dilution, Volatility, Cash flow, and News.

What every line is worth, and the reason behind it, on GKOS and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 7:12 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How GKOS ranks in Medical Devices

GKOS is #15 of 87 by Quality Score.

How GKOS ranks in Medical Devices
RankStockQuality Score
15Glaukos (GKOS) logoGKOSGlaukos12

Share count against a year before: GKOS +3%, HTFL +78%, TFX -6.2%, HAE -4.4%.

More in Medical Devices

When does GKOS report earnings, and what happens after?

Expected to report Tue Feb 16, after the close (in 90 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What GKOS reported on Oct 28, 2026

The quarter

Sales of $211.0M, 58% more than a year ago; a profit of $0.03 a share, from a loss of $0.28.

“Our third quarter record results reflect a sustained growth acceleration in our business with the strong performance driven by growing iDose® TR adoption and utilization, along with our broader Interventional Glaucoma, or IG, initiatives globally, as well as growing contributions of Epioxa®.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

Where the quarter's sales came from
LineQ3
2026
Q2
2026
Q3
2025
By product
Glaucomaup 38%$152M72%$155M84%$110M83%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 28)

3 more lines, for Pro members.

The outlook

The outlook the company gave, by period
MeasureFigure
FY 2026
Net sales$775M to $785Mraised

Figures as filed (SEC filing, Oct 28)

1 more outlook line, for Pro members.

The numbers

Market value
$15B
today
Sales
$690M
up 46.9% on the year
Free cash flow
$36M
last 12 months

Sales grew 18% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 5.1% a year over 5 years.

4 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on GKOS: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+22.8%+4.2%+33.6%
Apr 29Jul 29Oct 28
ReportedGapReaction5
days
Oct 28, 2026After close+16.3%+33.6%+36.0%
Jul 29, 2026After close+11.5%+4.2%+5.7%
Apr 29, 2026After close+21.0%+22.8%+15.7%

GKOS closed higher after 4 of its last 4 reports.

All 4 reports, and GKOS's Quality Score going into each

GKOS sales and profit by year

Sales and profit by year

Sales grew in five of the last seven years, to $507M in 2025. It made a profit in one of the eight years.

GKOS has 4 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on GKOS, and all 14 on every stock.Get in free →

GKOS RSI today: 59.5, above its 50-day and 200-day averages

Not scored

RSI 59.5, MACD below signal, above both averages. Not scored.

The deep dive on GKOS

7 more findings on GKOS, each with its source, for Pro members.

GKOS insider trades

4 insiders sold $25.1M across 12 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellGilbert H. Kliman$633KDirectorat $253.00 on Nov 4, filed Nov 5

All 12 insider filings on GKOS from the last six months, for Pro members.

All GKOS insider trades

GKOS trades by Congress and the executive branch

3 trades disclosed in the last six months. The newest:

SellDonald Trump$50K to $100KPresident (R)traded Jul 29, disclosed Sep 22(55 days later)
All 3 trades on GKOS disclosed by Congress and the executive branch, for Pro members.Get in free →

See what Congress is buying across the market

GKOS's officers and directors

Officers and directors with a Form 4 in the last 12 months.

3 more officers and directors file at GKOS.

See insider trades by person

Which ETFs hold GKOS?

In ETFs: GKOS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Glaukos

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

1,094 employeesAliso Viejo, CAglaukos.com

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on GKOS and every other stock.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would move GKOS's score: 3 things
  • 3 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawayAug 22Donald Trump bought GKOS$1K to $15K, disclosed Aug 22

Alerts are optional.

See GKOS's 14 chart checks

See it live, free until Friday morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 18, 2026: GKOS's Quality Score is 12 (Above Average), #15 of 87 in Medical Devices. Insiders sold $25.1M in the last 6 months (Form 4).

What does GKOS's Quality Score say?

GKOS scores 12 today, which Breakaway calls Above Average. It is #15 of 87 in Medical Devices by Quality Score, with 4 of 14 chart checks firing. Up 390% over five years while the S&P 500 rose 67%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is GKOS's Quality Score?

GKOS scores 12 today, which Breakaway calls Above Average (11 to 14). That is #15 of 87 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind GKOS's 12.

Are insiders buying GKOS?

4 insiders sold $25.1M across 12 filings in the last 6 months. No open-⁠market buys on record. The newest is Gilbert H. Kliman, Director, who sold $633K on Nov 4. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,147 stocks ranked

See it live, free until Friday morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.